Design Therapeutics, Inc..
DSGN.US | Research and experimental development on natural sciences and engineering
Design Therapeutics, Inc. is a biotechnology company focused on developing disease-modifying therapies for serious degenerative disorders caused by nucleotide repeat expansions. Their platform focuses on addressing the underlying genetic cause of diseases like Friedreich ataxia (FA) and myotonic dys...Show More
Better Health for All
0
No evidence available to assess Design Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
Design Therapeutics, Inc. is a biotechnology company focused on developing therapies, not a financial institution that lends, insures, moves, or stores money for consumers. Therefore, most KPIs related to financial products, services, and customer financial outcomes are not applicable. The company expects to incur increasing operating losses for the foreseeable future, reporting a net loss of $11,105,000 for the three months ended March 31, 2024, and an accumulated deficit of $188,731,000 as of the same date.
1
As the company is operating at a loss, it has no profits to reinvest in community finance or profit-sharing initiatives.
Fair Pay & Worker Respect
0
No specific, concrete data points were found across the provided articles to assess Design Therapeutics, Inc. against the Fair Pay & Worker Respect ethical value. Information regarding employee compensation beyond CEO salary, pay equity, worker benefits, engagement, turnover, safety incidents, labor violations, or contract types is not available.
1
Fair Trade & Ethical Sourcing
0
The provided article, a corporate governance overview, does not contain any data relevant to fair trade, ethical sourcing, or any of the specified key metrics for this value.
1
Therefore, no assessment can be made based on the available evidence.
Honest & Fair Business
0
No evidence available to assess Design Therapeutics, Inc. on Honest & Fair Business.
Kind to Animals
-50
The company utilizes both animal and non-animal testing methods. Preclinical studies for DT-818 showed a greater than 90% reduction in toxic RNA foci in DM1 patient cells, indicating the use of in vitro (non-animal) assays.
1
However, animal studies were also conducted to assess the tolerability and distribution of DT-168 eye drops.
2
The company does not explicitly state an animal testing policy.
3
No specific data on the volume or number of animals used in testing is provided.
4
No War, No Weapons
0
No specific, concrete evidence was found in the provided articles regarding Design Therapeutics, Inc.'s involvement in arms manufacturing, military contracts, conflict facilitation, or related policies and investments. The articles offer a general ESG risk rating and a corporate governance overview, but do not contain data points relevant to any of the 'No War, No Weapons' KPIs.
Planet-Friendly Business
0
No relevant evidence was found in the provided articles to assess DSGN.US against the 'Planet-Friendly Business' ethical value. All articles either explicitly stated they did not contain data relevant to DSGN.US or planet-friendly business metrics, or the content was unavailable for summarization.
Respect for Cultures & Communities
0
No evidence available to assess Design Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
-20
Design Therapeutics, Inc. has no documented data breaches.
1
The company's Code of Business Conduct and Ethics states that employees must never collect more personal information than legitimately needed, use it only for the purpose for which it was collected, and retain it only as long as needed, aligning with good data minimization practices.
2
However, specific retention periods are not detailed. The company acknowledges the use of generative AI by employees and that its disclosure and use of personal data in AI technologies are subject to privacy laws.
3
The Audit Committee reviews material risks related to artificial intelligence.
4
The company is subject to stringent and changing U.S. and foreign laws, regulations, and rules related to data privacy and security, including the EU GDPR, UK GDPR, CCPA, and HIPAA, and mentions potential fines for non-compliance.
5
The Code of Business Conduct and Ethics outlines principles for handling personal information, including collecting only necessary data, using it for its intended purpose, and retaining it only as long as needed.
6
However, it does not detail specific user control mechanisms or privacy settings beyond these general principles. The company mentions taking steps designed to detect, mitigate, and remediate vulnerabilities in information systems, but no specific patching timeframes or program details are provided.
7
The Code of Business Conduct and Ethics includes principles of data minimization and purpose limitation, indicating some privacy considerations in development.
8
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding DSGN.US's performance on any of the Zero Waste & Sustainable Products KPIs. The articles primarily covered general biotechnology industry news, funding, and regulatory updates, with no specific data on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1